Maricopa County health inspectors visited nearly 1,450 restaurants and other food-serving facilities; about 380 restaurants ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

A new study by the University of Oxford, published in the journal npj Vaccines, shows that a vaccine against respiratory ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

The FDA has expanded the approval of mResvia to include active immunization in high-risk individuals 18 through 59 years of age.

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Moderna receives US FDA approval for RSV vaccine, mResvia, in adults aged 18-59 at increased risk for RSV disease. News release. Moderna. June 12, 2025.

Abrysvo also is approved for prevention of LRTD caused by RSV in adults ages 18 to 59 years who are at increased risk, and for immunization in pregnancy at 32 to 36 weeks' gestational age for the ...

Merck & Co. won US approval for a shot that protects against RSV, the most common cause of hospitalization among infants.

RSV is a common respiratory virus that causes seasonal infections such as the flu, but is a leading cause of pneumonia and death in infants and US FDA approves Merck's RSV antibody for infants ...

Merck (MRK) stock is in focus as its Enflonsia RSV shot is cleared for infants in the U.S. in a market led by Sanofi (SNY) and AstraZeneca (AZN). Read more here.